Page 10«..9101112..2030..»

A Comprehensive Analysis of the Rheumatoid Arthritis Stem Cell Therapy Market Available in the Latest Report – Tech Admirers

By daniellenierenberg

Share

Share

Share

Email

With a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global rheumatoid arthritis stem cell therapy market as well as the factors responsible for such a growth. Our highly dedicated professionals have inputted critical and accurate insights associated with every industry, and region by doing thorough primary and secondary research.

We leverage space-age industrial and digitalization tools to provide avant-garde actionable insights to our clients regarding the rheumatoid arthritis stem cell therapy market. For enhancing readers experience, the report starts with a basic overview about the rheumatoid arthritis stem cell therapy market and its classification. Further, we have considered 2028 as the estimated year, 2018 2028 as the stipulated timeframe.

Competitive Assessment

The rheumatoid arthritis stem cell therapy market report includes global as well as emerging players:

The insights for each vendor consists of:

Obtain the Report TOC: https://www.factmr.com/connectus/sample?flag=T&rep_id=1001

Regional Analysis

Important regions covered in the rheumatoid arthritis stem cell therapy market report include:

The rheumatoid arthritis stem cell therapy market report also provides data regarding the key countries in the defined regions.

Segmentation Analysis

By Treatment Type:

By Distribution Channel:

What insights does the rheumatoid arthritis stem cell therapy market report provide to the readers?

Get the Report Sample here: https://www.factmr.com/connectus/sample?flag=S&rep_id=1001

Questionnaire answered in the rheumatoid arthritis stem cell therapy market report include:

Link:
A Comprehensive Analysis of the Rheumatoid Arthritis Stem Cell Therapy Market Available in the Latest Report - Tech Admirers

To Read More: A Comprehensive Analysis of the Rheumatoid Arthritis Stem Cell Therapy Market Available in the Latest Report – Tech Admirers
categoriaBone Marrow Stem Cells commentoComments Off on A Comprehensive Analysis of the Rheumatoid Arthritis Stem Cell Therapy Market Available in the Latest Report – Tech Admirers | dataNovember 23rd, 2019
Read All

‘It was unreal’: Mother of injured Bronco Ryan Straschnitzki stunned by his progress after surgery – Edmonton Sun

By daniellenierenberg

The mother of a hockey player paralyzed in the Humboldt Broncos bus crash says shes stunned by the progress he has made since receiving spinal surgery in Thailand.

Doctors implanted an epidural stimulator in Ryan Straschnitzkis spine earlier this month and a week later injected stem cells above and below the injury in the hope that will help reverse some of the damage.

Ryan Straschnitzki was presented a jersey as hockey players from the non-profit PX3 AMP Sledge Hockey Academy have been endorsed by the Calgary Flames as its affiliate sledge hockey team at the upcoming 2019 USA Hockey Sled Classic presented by the NHL in St. Louis from Nov. 21 Nov. 24, 2019 at the Scotiabank Saddledome in Calgary on Wednesday, October 30, 2019. Darren Makowichuk/PostmediaDarren Makowichuk / DARREN MAKOWICHUK/Postmedia

The 20-year-old from Airdrie, Alta., is to remain in Thailand until early December.

Hands down Im 200 per cent behind this. I didnt expect this kind of result this quickly, Michelle Straschnitzki said in an interview. Its definitely not a quick fix. Its not a cure, but its certainly progress and its more than weve had in 19 months.

Tom Straschnitzki, who is also in Thailand, has posted a number of videos of his sons rehab, including one where the young man was able to move a leg. Another video shows him strapped into a harness as physiotherapists slowly help him walk with the use of a machine on wheels.

Bout time he got off his ass. 1st time since he boarded the bus that horrendous day, Straschnitzki tweeted.

Therapist helping with knees and ankles so they dont buckle. Ryan did so good, I sent him to the beer store for me.

Straschnitzki was one of 13 players who were injured when an inexperienced truck driver blew through a stop sign and into the path of the Saskatchewan junior hockey teams bus in April 2018. Sixteen others on the bus died.

Straschnitzki, who was paralyzed from the chest down, has said he isnt expecting a cure but hopes the implant will restore some muscle movement and things such as bladder control.

A small device like a remote control is to send electrical currents to his spinal cord to try to stimulate nerves and move limbs. The implant is being programmed to stimulate certain nerves mapped out by surgeons and therapists.

The surgery can cost up to $100,000 and isnt covered by public health care or insurance, because the epidural procedure has not been approved by Health Canada. The family is paying for it themselves. It is also performed in countries such as the United States and Switzerland, but it is much cheaper in Thailand.

The players mother, who didnt go to Thailand, said hes been low key when shes talked to him.

In typical Ryan fashion hes very quiet. All he says is hes very tired and you can tell. His body, his mind, everything is tired because hes pushing as far as he can.

Her son takes part in nerve mapping in the morning, does physio in the afternoon and then does more work with the implant, she said. He still plans to hit the ice in Bangkok with his hockey sledge before returning home.

Straschnitzki said seeing her boys progress on the videos stunned her.

I was just absolutely floored. It obviously brought the tears. I was bawling. It was unreal, she said.

Tom said the last time Ryan walked was when he walked on the bus and then, to watch him moving his legs, walking essentially, that just rocked me.

Humboldt Broncos crash survivor Ryan Straschnitzki takes a moment during practice at Winsport in Calgary, on Aug. 7, 2018.Leah Hennel / Postmedia

More:
'It was unreal': Mother of injured Bronco Ryan Straschnitzki stunned by his progress after surgery - Edmonton Sun

To Read More: ‘It was unreal’: Mother of injured Bronco Ryan Straschnitzki stunned by his progress after surgery – Edmonton Sun
categoriaSpinal Cord Stem Cells commentoComments Off on ‘It was unreal’: Mother of injured Bronco Ryan Straschnitzki stunned by his progress after surgery – Edmonton Sun | dataNovember 23rd, 2019
Read All

Biobots are hybrid machines that have muscles and nerves – DesignNews

By daniellenierenberg

An artist rendering of a new generation of biobots developed by researchers at the University of Illinois--soft robotic devices powered by skeletal muscle tissue stimulated by on-board motor neurons. (Image source: Michael Vincent)

The next-generation of medical treatment and diagnosis likely will include tiny robots that can explore inside the human body and perform appointed tasks.

To drive this technological aim, researchers at the University of Illinois have developed soft, biological robotic devices that are self-driven using light-stimulated neuromuscular tissue and have intelligence, memory, and learning ability. The work brings researchers a step closer toward the development of autonomous biobots.

This is the first milestone towards intelligent biorobots that make themselves through self assembly, project leader Taher Saif, a mechanical science and engineering professor from the University of Illinois, told Design News.

Muscle cells mixed with an extra cellular matrix is dropped on the tail part, where muscle cells form the muscle tissue by self assembly, Saif told Design News. Neurons are placed on the head part of the swimmer from where they spread out and form junctions with the muscle. These neurons then fire and make the muscle contract.

The researchers published a paper on their recent work in the journal Proceedings of the National Academy of Sciences.

The recent work is a continuation of Saifs research on similar technology. In 2014, research teams led by Saif and a colleague, bioengineering professor Rashid Bashir, developed the first self-propelled biohybrid robots that could swim and walk, powered by beating cardiac muscle cells derived from rats.

While those robots could move on their own using biomaterials, they couldnt sense the environment or make decisions, Saif said.

The current work takes this technology a step further with biobots powered by skeletal muscle tissue and stimulated by on-board motor neurons, he said. The neurons have optogenetic properties derived from mouse stem cells; when exposed to light, they fire to actuate the muscle tissue.

Neurons make connections between each other forming a neural network, Saif explained. Some of the neurons form junctions with the muscle. The neurons fire and stimulate the muscle.

Once the muscle is stimulated, it contracts and moves the tails of the swimming biobot, Saif said. This motion of the tails make the swimmer propel forward.

Once the researchers ensured that the neuromuscular tissue used in the biobots was compatible with the synthetic biobot skeletons, they then set about to optimize the abilities of the swimming device. In particular, they aimed for the bot to be able to respond intelligently to environment cues by integrating neural units within biohybrid systems.

Given our understanding of neural control in animals, it may be possible to move forward with biohybrid neuromuscular design by using a hierarchical organization of neural networks, Saif said in a press statement.

Once these smart biobots are optimized, Saif and his team believe they can be used for various applications in bioengineering, medicine, and self-healing materials and technologies.

In the future, it is possible that such intelligent micro biorobots may swim towards a target tissue inside the body and deliver drugs on an on-demand basis, Saif told Design News.

The team plans to continue its work by exploring the use of multiple types of neurons in the biobot as well as to test the robots ability to sense and fire when a threshold signal such as a chemical gradient is exceeded.

Elizabeth Montalbano is a freelance writer who has written about technology and culture for more than 20 years. She has lived and worked as a professional journalist in Phoenix, San Francisco and New York City. In her free time she enjoys surfing, traveling, music, yoga and cooking. She currently resides in a village on the southwest coast of Portugal.

January 28-30:North America's largest chip, board, and systems event,DesignCon, returns to Silicon Valleyfor its 25th year!The premier educational conference and technology exhibition, this three-day event brings together the brightest minds across the high-speed communications and semiconductor industries, who are looking to engineer the technology of tomorrow. DesignCon is your rocket to the future. Ready to come aboard?Register to attend!

See the article here:
Biobots are hybrid machines that have muscles and nerves - DesignNews

To Read More: Biobots are hybrid machines that have muscles and nerves – DesignNews
categoriaCardiac Stem Cells commentoComments Off on Biobots are hybrid machines that have muscles and nerves – DesignNews | dataNovember 23rd, 2019
Read All

CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia – Business Wire

By daniellenierenberg

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved CALQUENCE (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The US approval was granted under the FDAs Real-Time Oncology Review and newly established Project Orbis programs.

The approval is based on positive results from the interim analyses of two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and ASCEND in patients with relapsed or refractory CLL. Together, the trials showed that CALQUENCE in combination with obinutuzumab or as a monotherapy significantly reduced the relative risk of disease progression or death versus the comparator arms in both 1st-line and relapsed or refractory CLL. Across both trials, the safety and tolerability of CALQUENCE were consistent with its established profile.

Dave Fredrickson, Executive Vice President, Oncology Business Unit said: With over 20,000 new cases anticipated this year in the US alone, todays approval of CALQUENCE provides new hope for patients with one of the most common types of adult leukemia, offering outstanding efficacy and a favorable tolerability profile. The chronic lymphocytic leukemia patient population is known to face multiple comorbidities, and tolerability is a critical factor in their treatment.

Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute, Medical Director of Hematology Research for The US Oncology Network, and a lead author of the ELEVATE-TN trial, said: Tolerability remains an issue in the current treatment landscape of chronic lymphocytic leukemia, which may require ongoing therapy for many years. In the ELEVATE-TN and ASCEND trials comparing CALQUENCE to commonly used treatment regimens, CALQUENCE demonstrated a clinically meaningful improvement in progression-free survival in patients across multiple settings, while maintaining its favorable tolerability and safety profile.

The results of the interim analysis of the ELEVATE-TN trial will be presented at the upcoming American Society of Hematology congress.

The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with either CALQUENCE in combination with obinutuzumab or CALQUENCE monotherapy versus chlorambucil chemotherapy plus obinutuzumab, a current standard-of-care combination used in the control arm.

In the CALQUENCE combination arm, risk of disease progression or death was reduced by 90% (HR 0.10; 95% CI, 0.06-0.17, p<0.0001) and in the monotherapy arm it was reduced by 80% (HR 0.20; 95% CI, 0.13-0.30, p<0.0001).

The median time to disease progression for patients treated with CALQUENCE in combination with obinutuzumab or as a monotherapy has not yet been reached vs. 22.6 months (95% CI, 20-28) for chlorambucil plus obinutuzumab.

ELEVATE-TN safety overview (most common ARs*, 15%):

Adverse reaction

CALQUENCE plus obinutuzumab(n=178)

CALQUENCE monotherapy(n=179)

Chlorambucil plus obinutuzumab(n=169)

Any

Grade 3

Any

Grade 3

Any

Grade 3

Infection

69%

22%

65%

14%

46%

13%

Neutropenia

53%

37%

23%

13%

78%

50%

Anemia

52%

12%

53%

10%

54%

14%

Thrombocytopenia

51%

12%

32%

3.4%

61%

16%

Headache

40%

1.1%

39%

1.1%

12%

0

Diarrhea

39%

4.5%

35%

0.6%

21%

1.8%

Musculoskeletal pain

37%

2.2%

32%

1.1%

16%

2.4%

Fatigue

34%

2.2%

23%

1.1%

24%

1.2%

Bruising

31%

0

21%

0

5%

0

Rash

26%

2.2%

25%

0.6%

9%

0.6%

Arthralgia

22%

1.1%

16%

0.6%

4.7%

1.2%

Dizziness

20%

0

12%

Visit link:
CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - Business Wire

To Read More: CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia – Business Wire
categoriaCardiac Stem Cells commentoComments Off on CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia – Business Wire | dataNovember 23rd, 2019
Read All

Scientists find a cell that helps tadpoles tails regrow – North Coast Courier

By daniellenierenberg

Aristotle already observed in the fourth century B.C. that some animals can regrow their tails after losing them, but the mechanisms that support this kind of regeneration remain difficult to understand.

Using single-cell genomics, scientists at the Wellcome Trust / Cancer Research UK Gurdon Institute at the University of Cambridge developed an innovative strategy to show what happens in different tadpole cells when they regenerate their tails.

Recent advances at Cambridge in next-generation single-cell sequencing mean that scientists can now track which genes are turned on throughout a whole organism or tissue, at the resolution of individual cells. This technique, known as single-cell genomics, makes it possible to distinguish between cell types in more detail based on their characteristic selection of active genes.

These groundbreaking discoveries are beginning to reveal a map of cellular identities and lineages, as well as the factors involved in controlling how cells choose between alternative pathways during embryo development to produce the range of cell types in adults.

Using this technology, Can Aztekin and Dr Tom Hiscock under the direction of Dr Jerome Jullien made a detailed analysis of cell types involved in regeneration after damage in African clawed frog tadpoles (Xenopus laevis). Details were published in the journal Science.

Dr Tom Hiscock said: Tadpoles can regenerate their tails throughout their life; but there is a two-day period at a precise stage in development where they lose this ability. We exploited this natural phenomenon to compare the cell types present in tadpoles capable of regeneration and those no longer capable.

The researchers found that the regenerative response of stem cells is orchestrated by a single sub-population of skin cells, which they named Regeneration-Organizing Cells, or ROCs.

Can Aztekin said: Its an astonishing process to watch unfold. After tail amputation, ROCs migrate from the body to the wound and secrete a cocktail of growth factors that coordinate the response of tissue precursor cells. These cells then work together to regenerate a tail of the right size, pattern and cell composition.

In mammals, many tissues such as the skin epidermis, the intestinal epithelium and the blood system, undergo constant turnover through life. Cells lost through exhaustion or damage are replenished by stem cells. However, these specialised cells are usually dedicated to tissue sub-lineages, while the ability to regenerate whole organs and tissues has been lost in all but a minority of tissues such as liver and skin.

Professor Benjamin Simons, a co-author of the study said: Understanding the mechanisms that enable some animals to regenerate whole organs represents a first step in understanding whether a similar phenomenon could be reawakened and harnessed in mammalian tissues, with implications for clinical applications.

This research was funded by the University of Cambridge, the Cambridge Trust andthe Wellcome Trust;and supported by theEuropean Molecular Biology Organization, the Royal Society,theEuropean Molecular Biology Laboratory, and Cancer Research UK.

Source: University of Cambridge Research

Visit link:
Scientists find a cell that helps tadpoles tails regrow - North Coast Courier

To Read More: Scientists find a cell that helps tadpoles tails regrow – North Coast Courier
categoriaSkin Stem Cells commentoComments Off on Scientists find a cell that helps tadpoles tails regrow – North Coast Courier | dataNovember 22nd, 2019
Read All

‘I was bawling’: Injured Bronco’s mother stunned by his progress after surgery – Airdrie Today

By daniellenierenberg

The mother ofa hockey player paralyzed in the Humboldt Broncos bus crash says she's stunned by the progress he has made since receiving spinal surgery in Thailand.

Doctors implanted an epidural stimulator in Ryan Straschnitzki's spine earlier this monthand a week later injected stem cells above and below the injury in the hope thatwill help reverse some of the damage.

The 20-year-old from Airdrie, Alta., is to remain in Thailand until early December.

"Hands down I'm 200 per cent behind this. I didn't expect this kind of result this quickly," Michelle Straschnitzki said in aninterview. "It's definitely not a quick fix. It's not a cure, but it's certainly progress and it's more than we've had in 19 months."

Tom Straschnitzki, who is also inThailand,has posted a number of videos of his son's rehab, including one where the young manwas able to move a leg. Another video shows him strapped into a harness as physiotherapists slowly help him walk with the use of a machine on wheels.

"Bout time he got off his ass. 1st time since he boarded the bus that horrendous day," Straschnitzki tweeted.

"Therapist helping with knees and ankles so they don't buckle. Ryan did so good, I sent him to the beer store for me."

Straschnitzki was one of 13 players who were injured when an inexperienced truck driver blew through a stop sign and into the path of the Saskatchewan junior hockey team's bus in April 2018. Sixteen others on the bus died.

Straschnitzki, who was paralyzed from the chest down, has said he isn't expecting a cure but hopes the implant will restore some muscle movement and things such as bladder control.

A small device like a remote control is to send electrical currents to his spinal cord to try to stimulate nerves and move limbs. The implant is being programmed to stimulate certain nerves mapped out by surgeons and therapists.

The surgery can cost up to $100,000 and isn't covered by publichealth care or insurance, because the epidural procedure has not been approved by Health Canada.The familyis paying for it themselves. It is also performed in countries such as the United States and Switzerland, but it is much cheaper in Thailand.

The player's mother, who didn't go to Thailand, said he's been low key when she's talked to him.

"Intypical Ryan fashion he's very quiet. All he says is he's very tired and you can tell. His body, his mind, everything is tired because he's pushing as far as he can."

Her sontakes part in nerve mappingin the morning, does physio in the afternoon and then does more work with the implant, she said. He still plans to hit the ice in Bangkokwith his hockey sledge before returning home.

Straschnitzkisaid seeingher boy'sprogress on the videos stunned her.

"I was just absolutely floored. It obviously brought the tears. I was bawling. It was unreal," she said.

"Tom said the last time Ryan walked was when he walked on the bus and then, to watch him moving his legs, walking essentially, that just rocked me."

This report by The Canadian Press was first published Nov. 22, 2019.

Follow @BillGraveland on Twitter

Bill Graveland, The Canadian Press

Original post:
'I was bawling': Injured Bronco's mother stunned by his progress after surgery - Airdrie Today

To Read More: ‘I was bawling’: Injured Bronco’s mother stunned by his progress after surgery – Airdrie Today
categoriaSpinal Cord Stem Cells commentoComments Off on ‘I was bawling’: Injured Bronco’s mother stunned by his progress after surgery – Airdrie Today | dataNovember 22nd, 2019
Read All

Suspended animation induced in humans for the first time – CNET

By daniellenierenberg

Surgeons in the operating room. Researchers at the University of Maryland believe rapidly cooling the body could put patients into a state of suspended animation.

A team of surgeons at the University of Maryland School of Medicine have placed a human patient in "suspended animation" for the first time, according to a report by New Scientist on Wednesday. The procedure is intended to prolong the time surgeons have to fix traumatic injuries by deliberately lowering patients' body temperatures.

The Emergency Preservation and Resuscitation (EPR) for Cardiac Arrest From Trauma (EPR-CAT) trial has been in the works since 2010 and intends to rapidly cool the body of patients presenting with extreme trauma -- like a gunshot or knife wound. The prognosis for this type of trauma is grim: Due to rapid blood loss, these patients go into cardiac arrest. With the heart stopped, there's only minutes for surgeons to stem the bleeding and get the heart pumping again before damage occurs. The odds of survival are between 2 to 5%.

Even if patients survive, the lack of oxygen caused by the injuries can result in permanent damage to the brain.

Samuel Tisherman, who is overseeing the EPR-CAT trial, suspects that rapid cooling or "induced hypothermia" can buy trauma patients extra time.

The clinical trial aims to alter the body's temperature by about 27 degrees Celsius, dropping it below 10 degrees Celsius (50 degrees Fahrenheit) with an ice-cold saline solution. In computing parlance, the idea is that induced hypothermia puts the body into a sort of "standby" mode. Metabolic processes slow down, our cells don't need as much oxygen and so cell damage is prevented. When the wounds are repaired, the system can be rebooted -- hopefully with no long-lasting effects to the hardware.

There's sound scientific reason to believe rapid cooling can achieve such miraculous feats.

The New York Times reported a similar trial in dogs (with the somewhat alarming headline "Zombie Dogs") in December 2005, where canines ventured into the afterlife and back again. After having their blood drained and going into cardiac arrest, the dogs were pumped full of a cool saline solution. Clinically, doctors would say the dogs were dead, but after three hours, the saline solution was replaced with blood and the dogs were warmed. They survived. Importantly, they didn't seem to suffer from any severe neurological deficits.

A cohort of 20 patients will be enrolled in the study -- 10 will receive EPR, 10 will not. Trauma patients can not consent to taking part in the trial, but the US Food and Drug Administration approved the trial on the proviso there is no alternative treatment, while also consulting with members of the community and allowing anyone to opt out, should they choose.

No results have been released but Tisherman discussed the trial at a symposium at the New York Academy of Sciences on Monday, revealing his team had trialed the suspended animation technique in one patient. The expected completion date is December 2019, with full results expected by the end of 2020.

Originally published 3:43 p.m PT

Read the original here:
Suspended animation induced in humans for the first time - CNET

To Read More: Suspended animation induced in humans for the first time – CNET
categoriaCardiac Stem Cells commentoComments Off on Suspended animation induced in humans for the first time – CNET | dataNovember 22nd, 2019
Read All

CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia – BioSpace

By daniellenierenberg

The approval is based on positive results from the interim analyses of two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and ASCEND in patients with relapsed or refractory CLL. Together, the trials showed that CALQUENCE in combination with obinutuzumab or as a monotherapy significantly reduced the relative risk of disease progression or death versus the comparator arms in both 1st-line and relapsed or refractory CLL. Across both trials, the safety and tolerability of CALQUENCE were consistent with its established profile.

Dave Fredrickson, Executive Vice President, Oncology Business Unit said: With over 20,000 new cases anticipated this year in the US alone, todays approval of CALQUENCE provides new hope for patients with one of the most common types of adult leukemia, offering outstanding efficacy and a favorable tolerability profile. The chronic lymphocytic leukemia patient population is known to face multiple comorbidities, and tolerability is a critical factor in their treatment.

Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute, Medical Director of Hematology Research for The US Oncology Network, and a lead author of the ELEVATE-TN trial, said: Tolerability remains an issue in the current treatment landscape of chronic lymphocytic leukemia, which may require ongoing therapy for many years. In the ELEVATE-TN and ASCEND trials comparing CALQUENCE to commonly used treatment regimens, CALQUENCE demonstrated a clinically meaningful improvement in progression-free survival in patients across multiple settings, while maintaining its favorable tolerability and safety profile.

The results of the interim analysis of the ELEVATE-TN trial will be presented at the upcoming American Society of Hematology congress.

The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with either CALQUENCE in combination with obinutuzumab or CALQUENCE monotherapy versus chlorambucil chemotherapy plus obinutuzumab, a current standard-of-care combination used in the control arm.

In the CALQUENCE combination arm, risk of disease progression or death was reduced by 90% (HR 0.10; 95% CI, 0.06-0.17, p<0.0001) and in the monotherapy arm it was reduced by 80% (HR 0.20; 95% CI, 0.13-0.30, p<0.0001).

The median time to disease progression for patients treated with CALQUENCE in combination with obinutuzumab or as a monotherapy has not yet been reached vs. 22.6 months (95% CI, 20-28) for chlorambucil plus obinutuzumab.

ELEVATE-TN safety overview (most common ARs*, 15%):

Adverse reaction

CALQUENCE plus obinutuzumab(n=178)

CALQUENCE monotherapy(n=179)

Chlorambucil plus obinutuzumab(n=169)

Any

Grade 3

Any

Grade 3

Any

Grade 3

Infection

69%

22%

65%

14%

46%

13%

Neutropenia

53%

37%

23%

13%

78%

50%

Anemia

52%

12%

53%

10%

54%

14%

Thrombocytopenia

51%

12%

32%

3.4%

61%

16%

Headache

40%

1.1%

39%

1.1%

12%

0

Diarrhea

39%

4.5%

35%

0.6%

21%

1.8%

Musculoskeletal pain

37%

2.2%

32%

1.1%

16%

2.4%

Fatigue

34%

2.2%

23%

1.1%

24%

1.2%

Bruising

31%

0

21%

0

5%

0

Rash

26%

2.2%

25%

0.6%

9%

0.6%

Arthralgia

22%

1.1%

16%

0.6%

4.7%

1.2%

Dizziness

20%

0

12%

0

See the article here:
CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - BioSpace

To Read More: CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia – BioSpace
categoriaCardiac Stem Cells commentoComments Off on CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia – BioSpace | dataNovember 22nd, 2019
Read All

AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting – P&T Community

By daniellenierenberg

NORTH CHICAGO, Ill., Nov. 21, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that more than 40 abstracts, including 18 oral presentations, will be presented during the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition, December 7-10, in Orlando, FL. New data include presentations on Ibrutinib (IMBRUVICA) plus venetoclax (VENCLEXTA/VENCLYXTO) among others.

"At this year's ASH Annual Meeting, AbbVie will showcase the latest scientific progress from our portfolio spanning various hematologic malignancies," said Mohamed Zaki, M.D., Ph.D., Head of Hematology Oncology, AbbVie. "We look forward to sharing the new data from our clinical development programs for ibrutinib and venetoclax, which continue to demonstrate the potential to transform care and improve the lives of people living with various difficult-to-treat blood cancers."

Data from two studies of ibrutinib combination regimens in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) will be featured in the CLL Therapy Oral Session. A new minimal residual disease (MRD)-guided analysis from the Phase 2 CAPTIVATE study (PCYC-1142) of ibrutinib in combination with venetoclax will be presented (Abstract #35), as well as longer-term outcomes data from the Phase 3 E1912 study of ibrutinib in combination with rituximab, which served as the basis of a recent U.S. Food and Drug Administration (FDA) sNDA submission (Abstract #33). In addition, extended follow-up data of up to 7.5 years in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) supporting the long-term disease control and tolerability with ibrutinib (Abstract #1538) and a four-year updated analysis from the Phase 3 MURANO trial of venetoclax in combination with rituximab will be shared (Abstract #355).

These new data will provide insights on the ongoing evaluation of ibrutinib (IMBRUVICA) and venetoclax (VENCLEXTA/VENCLYXTO)use among a variety of CLL patients.

Details about presentations are as follows:

Abstract

Presentation Timing

Ibrutinib

Ibrutinib Plus Venetoclax for First-line Treatment of CLL/SLL: Results from the MRD Cohort of Phase 2 CAPTIVATE Study (PCYC-1142); Tam et al.; Abstract #35

Saturday, December 7

Oral Session: 7:30 a.m. 9:00 a.m. ET

Oral Presentation: 8:30 a.m. ET

Ibrutinib and Rituximab Compared to FCR in Younger Patients with CLL: Extended Follow-Up from the E1912 Trial; Shanafelt et al.; Abstract #33*

Saturday, December 7

Oral Session: 7:30 a.m. 9:00 a.m. ET

Oral Presentation: 8:00 a.m. ET

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory MCL with up to 7.5 Years of Extended Follow-up (MCL2001, MCL3001, CAN3001, PCYC-1104); Ruleet al.; Abstract #1538

Saturday, December 7

Poster Session: 5:30 p.m. 7:30 p.m. ET

Planned Analysis of the Phase 1/2 CIRLL Trial for CLL and MCL of Cirmtuzumab in Combination with Ibrutinib; Choi et al.; Abstract #1755

Saturday, December 7

Poster Session: 5:30 p.m. 7:30 p.m. ET

Clinical Impact of Ibrutinib with R-CHOP in UntreatedNon-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 PHOENIX Trial; Johnson et al.; Abstract #354**

Sunday, December 8

Oral Session: 7:30 a.m. 9:00 a.m. ET

Oral Presentation: 8:45 a.m. ET

Using Ibrutinib in Earlier Lines of Treatment in CLL/SLL (RESONATE/RESONATE-2); Barr et al.; Abstract #3054

Sunday, December 8

Poster Session: 6:00 p.m. 8:00 p.m. ET

Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory Non-germinal Center B CellLike (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL) (PCYC-1123); Ramchandren et al.; Abstract #761

Monday, December 9

Oral Session: 2:45 p.m. 4:15 p.m. ET

Oral Presentation: 3:45 p.m. ET

Venetoclax

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Saturday, December 7

Oral Session: 7:30 a.m. 9:00 a.m. ET

Oral Presentation: 8:30 a.m. ET

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD After Fixed-Duration Chemotherapy-Free Treatmentand Serves as Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 trial

Saturday, December 7

Oral Session: 7:30 a.m. 9:00 a.m. ET

Oral Presentation: 8:45 a.m. ET

T(11;14) and High BCL2 Expression are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 BELLINI Study

Saturday, December 7

Oral Session: 9:30 a.m. 11:00 a.m. ET

Oral Presentation: 10:15 a.m. ET

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Saturday, December 7

Oral Session: 12:00 p.m. 1:30 p.m. ET

Oral Presentation: 12:45 p.m. ET

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)Ineligible for Cytotoxic Chemotherapy

Saturday, December 7

Oral Session: 2:00 p.m. 3:30 p.m. ET

Oral Presentation: 2:00 p.m. ET

Outcomes After Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Saturday, December 7

Oral Session: 2:00 p.m. 3:30 p.m. ET

Oral Presentation: 3:15 p.m. ET

Safety and Efficacy of Venetoclax in Combinationwith Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Saturday, December 7

Oral Session: 4:00 p.m. 5:30 p.m. ET

Oral Presentation: 4:30 p.m. ET

Four-Year Analysis of MURANO Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Sunday, December 8

Oral Session: 7:30 a.m. 9:00 a.m. ET

Oral Presentation: 7:30 a.m. ET

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax andRituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the MURANO Trial

Sunday, December 8

Oral Session: 7:30 a.m. 9:00 a.m. ET

Oral Presentation: 7:45 a.m. ET

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax as Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Monday, December 9

Oral Session: 7:00 a.m. 8:30 a.m. ET

Oral Presentation: 7:00 a.m. ET

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Nave Patients with Higher-Risk Myelodysplastic Syndrome

Monday, December 9

Oral Session: 7:00 a.m. 8:30 a.m. ET

Oral Presentation: 7:45 a.m. ET

Biomarker Modulation by Mivebresib (ABBV-075) +/ Venetoclax in Relapsed/Refractory Acute MyeloidLeukemia

Monday, December 9

Oral Session: 7:00 a.m. 8:30 a.m. ET

Oral Presentation: 8:00 a.m. ET

Response to Venetoclax in Combination with LowIntensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Monday, December 9

Oral Session: 7:00 a.m. 8:30 a.m. ET

Oral Presentation: 8:15 a.m. ET

First Analysis from a Phase 1/2 Study of Venetoclaxin Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Monday, December 9

Oral Session: 6:15 p.m. 7:45 p.m. ET

Oral Presentation: 6:15 p.m. ET

Phase 1/2 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone as Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Monday, December 9

Oral Session: 6:15 p.m. 7:45 p.m. ET

Oral Presentation: 6:30 p.m. ET

Navitoclax

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Monday, December 9

Oral Session: 10:30 a.m. 12:00 p.m. ET

Oral Presentation: 11:30 a.m. ET

*Abstract was submitted by the National Cancer Institute

Read more from the original source:
AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting - P&T Community

To Read More: AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting – P&T Community
categoriaCardiac Stem Cells commentoComments Off on AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting – P&T Community | dataNovember 22nd, 2019
Read All

Cell Separation Technology Market Growth Forecast through 2019-2027 with Upcoming Trends and Market Opportunities – Montana Ledger

By daniellenierenberg

Transparency Market Research (TMR)has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~US$ 5 Bnin 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Request PDF Brochure of the Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration(CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

Global Cell Separation Technology Market: Segmentation

Cell Separation Technology Market by Technology

Cell Separation Technology Market by Application

Cell Separation Technology Market by End User

Cell Separation Technology Market by Region

Read more:
Cell Separation Technology Market Growth Forecast through 2019-2027 with Upcoming Trends and Market Opportunities - Montana Ledger

To Read More: Cell Separation Technology Market Growth Forecast through 2019-2027 with Upcoming Trends and Market Opportunities – Montana Ledger
categoriaCardiac Stem Cells commentoComments Off on Cell Separation Technology Market Growth Forecast through 2019-2027 with Upcoming Trends and Market Opportunities – Montana Ledger | dataNovember 22nd, 2019
Read All

Cell Separation Technology Market is Expected To Elevate To a Stellar Value of US$ 2.7 Bn by 2027 – Downey Magazine

By daniellenierenberg

Transparency Market Research (TMR)has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~US$ 5 Bnin 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies

Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Request a Sample of Cell Separation Technology Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process.

However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70% deaths are estimated to be caused by chronic diseases.

Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders.

This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products.

Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Request for a Discount on Cell Separation Technology Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1925

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

The rest is here:
Cell Separation Technology Market is Expected To Elevate To a Stellar Value of US$ 2.7 Bn by 2027 - Downey Magazine

To Read More: Cell Separation Technology Market is Expected To Elevate To a Stellar Value of US$ 2.7 Bn by 2027 – Downey Magazine
categoriaCardiac Stem Cells commentoComments Off on Cell Separation Technology Market is Expected To Elevate To a Stellar Value of US$ 2.7 Bn by 2027 – Downey Magazine | dataNovember 22nd, 2019
Read All

Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction…

By daniellenierenberg

OBJECTIVES:

Stem cell therapy is a promising approach in the treatment of acutemyocardial infarction(AMI). Mesenchymal stem cells (MSC) from bone marrow (BM-MSC) and adipose tissue (AT-MSC) are attractive and feasible for preclinical and clinical trials. In this study, we compared the therapeutic potential of BM-MSC and AT-MSC in repairing the hearts of rats with isoproterenol (ISO)-induced AMI.

Forty-two female rats were assigned into two groups; the optimization and the experimental group. The optimization groups were further subdivided into control group and the AMI induced group (using ISO). The experimental group was subdivided into AMI+cell-free media injected in the tail vein, AMI+BM-MSC, and AMI+AT-MSC groups treated with the intravenous injection of their respective cell types. Twenty-eight days after induction, electrocardiogram (ECG) was performed, and heart tissue samples were collected for histological assessment and cells tracing.

MSC therapy repaired cardiac functions shown by the restoration of ST segment, QT and QRS intervals in the ECG when compared to the AMI group. Infarct area was significantly decreased, and cardiac tissue regeneration signs were shown on histopathological examination.

Both MSC sources proved to be equally efficient in the assessed parameters.

Link:
Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction...

To Read More: Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction…
categoriaBone Marrow Stem Cells commentoComments Off on Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction… | dataNovember 22nd, 2019
Read All

Pricey stem cell treatments are being offered at more clinics. They may not be FDA-approved. – Virginian-Pilot

By daniellenierenberg

A salesman for years, he said he was won over by the seminars sales pitch. His feet go numb and cold, and he has nerve damage in his back, a bad right knee and inner-ear issues, he said. Its hard for him to walk on uneven surfaces, and he said he worries about falls. The presentation, which was not led by Claar, gave Timm hope that he might find relief. Hope, he said, led him to agree to pay nearly $10,000, according to his records, to have each of his feet injected with a shot of Whartons Jelly, a substance from the cushiony material inside an umbilical cord that includes stem cells.

Excerpt from:
Pricey stem cell treatments are being offered at more clinics. They may not be FDA-approved. - Virginian-Pilot

To Read More: Pricey stem cell treatments are being offered at more clinics. They may not be FDA-approved. – Virginian-Pilot
categoriaBone Marrow Stem Cells commentoComments Off on Pricey stem cell treatments are being offered at more clinics. They may not be FDA-approved. – Virginian-Pilot | dataNovember 22nd, 2019
Read All

Anton Ferdinand: Giving back to other people is where I feel Im best – The Guardian

By daniellenierenberg

Anton Ferdinand has faced an unenviable amount of obstacles on the way to achieving his dreams. He grew up on a council estate in Peckham where the shadow of his older brother, Rio, loomed large over his own aspirations. From as young as nine, his resolve was hardened by the people who told him he would never follow in his brothers footsteps and make it as a professional footballer. But when asked about the most challenging aspect of everything he has done, he delivers his answer with clarity.

The hardest part of my career has been the year that I lost my mum, he says. Ferdinand was in the midst of a stint at Southend in 2017 when his mother, Janice, died of breast cancer.

After struggling through seasons in Turkey and Thailand, he had rediscovered his passion for the game and as he thrived, so did his team as they rose up the table. Everything was going well until he learned how quickly life can change.

Football has always helped me deal with whatever Im dealing with off the pitch, he says. For that 90 minutes, for that couple of hours of training, my mind was clear and I was not thinking about what was going on; I was focused on football. But it was the first time in my life that football wasnt a get-out for me. I couldnt shake the loss of my mum. I was going on the pitch not caring how I played, not caring about the result because all I wanted was my mum.

His experience is another testimony to how little is known about the true driving factors behind an athletes form as fans celebrate and castigate with little empathy. Hearing fans going from cheering you to booing you? Inside, Im thinking: They dont even know what Im going through.

They dont know what happened but they dont even know what Im going through emotionally. They dont know that [for] the first time in my life Im struggling to deal with stuff thats happening in my life.

The reason Ferdinand agreed to speak is unrelated to his own loss. In 2018 a boy called Henry a classmate of his young son Flynn was diagnosed with aplastic anaemia, a rare blood cancer in which the bone marrow does not produce enough stem cells.

Despite a drive to sign potential donors to the DKMS stem cell register, Henry failed to find a suitable cell match and he died in June of this year. The difficulty of explaining to his son how a boy of the same age was no longer with them left an impression on Ferdinand. Since then, he has become an ambassador of DKMS, a blood cancer charity, and he has become close to Henrys father Gareth Walker, who joins him throughout the interview.

To be so close to the answer but for not enough [people] to know about it for there to be someone there to be able to donate, its entirely heartbreaking, says Walker. So, its just about not letting other people have to go through it.

Walker is admirable and strong, and he talks explicitly about the helplessness of losing his son; the lack of sleep, the fact that he and his wife, Kate, still have to be present and parents to their younger daughter, even though there are times when they want to hide from the world and getting out of bed seems impossible.

Through their grief he and his wife have found meaning in trying to raise awareness about the necessity to join the stem cell register in the hope that one day everyone will be able to find a match.

Blood cancer is a silent killer: each year more than 30,000 people are diagnosed with it in the UK and 12,000 die. In recent years, organ and blood donation have spilled into public consciousness but the concept of giving blood stem cells is unknown and feared.

After an international search had failed to find the perfect match, Walker donated his own stem cells to his son but that was not ideal either. He is now determined to ensure that people understand how easy the procedure was, which he likens to a simple blood transfusion.

When Anton said he was willing to help and became ambassador of the charity and everything, to me I cant tell you how grateful I am because fundamentally I dont have the platform, says Walker. I have the story, I have all the emotional heartstrings and stuff. Happy is the wrong word, but Ill sit here in this interview, Ill stand in front of audiences. Ill tell anyone whos willing to bloody listen about it and if the tragedy of the story helps get people motivated, its great.

Ferdinand listens with head bowed, nodding to practically each syllable. He seems to have found peace in his life beyond the familiar confines of a football pitch and it looks as if he is exactly where he wants to be. To be able to give back to other people, I just feel thats where Im best, he says. When my son gets a bit older, for my son to be able to look at me and know, Dad you played a part in continuing Henrys legacy, that means a lot to me I think thats where the second phase of my life is going to be.

Ferdinand is speaking at the offices of New Era Sports Management, the agency that has been helping him for five years towards the end of his career. He is 34 and remains active with an eye on playing again, but at one point he unintentionally refers to his career in the past tense.

No matter how and when it finishes, it has been a fulfilling journey. After high-profile stints at West Ham, Sunderland and Queens Park Rangers, he settled in Turkey for 18 months at Bursaspor and then Antalyaspor. He was unveiled as a player by Police United in Thailand but never played, returning to England at Reading for two years, and it was in 2016 that he finally found his feet in League One at Southend. Last season, he played 18 games for St Mirren.

It is clear his bitter departure from Southend is still on his mind. That hurt me I wanted to stay there because a year on from losing my mum I felt a bit better in myself. My hunger started to come back for football and I wanted to stay there and show the fans the club meant something to me and that it was just a blip in that year because of what happened to me personally. But I was never given that opportunity and I wasnt given that opportunity by a family friend of mine [the then manager Chris Powell], which hurt me even more.

Ferdinand frequently refers to retirement as the second phase of his life. Many footballers and athletes finish their short careers unable to come to terms with life without the weekly nerves and furious adrenaline, and quietly fall into crisis. He initially experienced similar sensations at the thought of retirement, but he has found clarity in his next journey.

I never understood mental health while I was playing I was always like: How can you be depressed? How can you have mental health issues? I never understood it until it was my time to stop playing football.

When it actually came, it wasnt easy. It was hard. I had moments where I didnt want to get out of bed. So, now, I understand So Im over that next phase and I now have a drive, got a goal of what I want to do. Part of that is giving back to the next generation within New Era and giving back to people I can help.

Continued here:
Anton Ferdinand: Giving back to other people is where I feel Im best - The Guardian

To Read More: Anton Ferdinand: Giving back to other people is where I feel Im best – The Guardian
categoriaBone Marrow Stem Cells commentoComments Off on Anton Ferdinand: Giving back to other people is where I feel Im best – The Guardian | dataNovember 22nd, 2019
Read All

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -…

By daniellenierenberg

CAMBRIDGE, Mass. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCytes Flow Electroporation technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.

Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCytes Flow Electroporation technology and ExPERT platform to develop up to five engineered cell therapies, including VOR33, Vors lead eHSC candidate, which is in development for acute myeloid leukemia (AML). In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.

Vor will use MaxCytes cell engineering platform to deliver its gene editing machinery into hematopoietic stem cells to remove biologically redundant cell surface proteins that are also expressed on blood cancer cells. Once the eHSCs are transplanted into a cancer patient, these cells are effectively hidden from complementary targeted therapies that target the relevant protein, while diseased cells are left vulnerable to attack. Vors approach thereby could unleash the potential of targeted therapies by broadening the therapeutic window and improving the utility of complementary targeted therapies.

MaxCyte is a leader in GMP electroporation technology, and we are thrilled that this agreement provides us with long-term access to a platform technology applicable to a pipeline of eHSC programs used to treat AML and other blood cancers, said Sadik Kassim, Ph.D., Chief Technology Officer of Vor. As we build on promising in vivo data from our lead candidate VOR33, we can now expand our manufacturing capabilities to support later-stage studies, regulatory filings and commercialization of VOR33.

MaxCytes ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

We look forward to expanding our relationship with Vor Biopharma as the company pioneers a potential future standard of care in hematopoietic stem cell transplants for cancer patients in need, said Doug Doerfler, President & CEO of MaxCyte. This agreement represents another key business milestone for MaxCyte, emphasizing the value of our technology platform applied to next-generation engineered cell therapies that may make a true difference in patient outcomes.

About VOR33Vors lead product candidate, VOR33, consists of engineered hematopoietic stem cells (eHSCs) that lack the protein CD33. Once these cells are transplanted into a cancer patient, CD33 becomes a far more cancer-specific target, potentially avoiding toxicity to the normal blood and bone marrow associated with CD33-targeted therapies. In so doing, Vor aims to improve the therapeutic window and effectiveness of CD33-targeted therapies, thereby potentially broadening the clinical benefit to patients suffering from AML.

About Vor BiopharmaVor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.

Vors platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments. A proof-of-concept study for Vors lead program has been published in Proceedings of the National Academy of Sciences.

Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil. Vor was founded by Dr. Mukherjee and PureTech Health and is supported by leading investors including 5AM Ventures and RA Capital Management, Johnson & Johnson Innovation JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research and Osage University Partners.

About MaxCyteMaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCytes mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit http://www.maxcyte.com.

See more here:
Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -...

To Read More: Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -…
categoriaBone Marrow Stem Cells commentoComments Off on Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -… | dataNovember 22nd, 2019
Read All

Count it all joy, Part III: Coach Hill-Eley has his own cancer struggle – Montgomery Advertiser

By daniellenierenberg

Autoplay

Show Thumbnails

Show Captions

Count It All Joy is a three-part series that unfolds the struggles of two Alabama State football playersas their parents battle a life-threatening disease. These circumstanceswould hit these players at a time whenlife is already hectic: football season. Here's how they got through and the testimony their parents carry.

In the distance, clouds mount across the skyline on the fringe of downtown Montgomery. They grow deeper in color as the weather evolves, the already ashen hues of the mass becoming a smoke grey that oddly soothes the eye because of its stark contrast with the taupe pavement of I-85 near Alabama State.

It was roughly 30 minutes before the 2 p.m. kickoff between ASU and Alcorn State, when the first strike of lightning split the sky of a previously sunny day, interrupting everything that was planned.

It was supposed to be a joyous day, and now an intimidating forecast of scattered thunderstorms painted weather radars in the area like a room full of toddlers left unattended with with green, yellow and red finger paint.

Prior to what would become a four-hour rain delay, the energy in ASU stadium was electric. The players were excited to challenge Alcorn State and possibly take the lead in the SWAC East standings. The ASU faithful wereon one accord with this sentiment, and most important of all, it was BeatOutBreastCancer Day, the Pink game and a general tribute to cancer survivors of any kind everywhere.

Yet in its present state, rain drenched the turf, spectators retreated from the elements under the cover of the bleachers, and under the awnings of the visitors' side concession stands. At that time, all the day had to show for itself was a chain of bras stretched out across the Alcorn State sideline that were supposed to serve as a tribute during the anticipated pregame celebration.

Save the bras, the field was desolate.

The joy, the energy was drained. The buzz that surrounded the day was washed away by the conditions of the day.

But in ASUs locker room, the day still shone brightly. The anticipation to take part in a celebration of life, trials and triumph never dwindled for Michael Jefferson II (MJ) or Darius King.

Katrice Williams and Micheal Jefferson Sr. stand on the sideline together, before "Beat out Breast Cancer" game with Alcorn State, Oct. 5.(Photo: Katrice Williams/contributed)

It was a day for them to honor the struggle of being alongside their respective parents in their fight against cancer. As they sat at their lockers waiting for the weather delay to end, itching to get on the field and play for their loved ones, their parents and the road they traveled occupied their minds.

I was going to go out and play for him, MJ said. During the delay, I was texting him before the game, and he was telling me Stay focused and play hard.

King described the moment, the anticipation, as a blessing. He said he thought about the pain she was going through, times they were in the hospital and, the pain on her face. It all flashed before him.

When the weather finally cleared, kickoff now set for 6 p.m., Michael Jefferson Sr. and Katrice Williams, the parents of MJ and King, respectively, went out for the coin toss as a tribute to their battle with cancer; as a tribute to their victories.

In the summer of 2017, Williams was diagnosed with stage 4 stomach cancer and declared cancer free in May 2018. As for Jefferson Sr., he overcame his second bout with leukemia in June 2018, but is still waiting for his body to accept his brother's stem cells from a bone marrow transplant in May.

Count it all Joy, Part 1: ASU WR Michael Jefferson II battles through fathers bout with cancer

Their testimony and journeys are why ASU head coach Donald Hill-Eley insisted they flip the coin to start the game, after approaching administration and Deputy Director of Athletics Terrance Jones earlier in the week to make sure it was fine for them to do so, since the event hinged on breast cancer awareness.

The courtesy was the least he could do, considering the role both parties played in his life over the past couple years, and vice versa.

The ASU football team arrives to Hornet Stadium before their contest against Alcorn State. (Photo: Kirsten Fiscus/Advertiser)

In December 2017, Hill-Eleys father Vincent Eley, 68, was diagnosed with throat cancer, a disease that will take the life of 3,760Americans this year, according to the American Society of Clinical Oncology (ASCO).

Fittingly, he and his fathers battle was wedged right in the middle of the battles of these two players. He could relate, he could support and he could be supported.

Shes been an inspiration for me, because a couple months later my dad was diagnosed with stage 4 cancer, Hill-Eley said. So, weve all been able to share whats going on ... then Mikes dad was diagnosed, so it became more of a support group than anything.

Thus, they all leaned on one another.

A lot of time I get strength from them, and they get strength from me, Hill-Eley said. Just trying to find a way to get through.

Cancer is a sickness that spreads. Not just in the nature of the disease, but it spreads and touches the lives of all involved, from the patient to their family and friends to the friends and family of the latter.

Cancer and its reach is best repressedand even healed through dependency. The dependency on one another, on loved ones and those willing to share the burden with you.

This is whats been happening behind the doors of ASUs program for the past two years.

Michael Jefferson II and his teammates visit Micheal Jefferson Sr.at the hospital(Photo: Michael Jefferson Sr./contributed)

Teammates, such as Jeremiah Hixon, were with MJ every step of the way. Hixon allowed Jefferson to take his car to Birmingham to see his dad in treatment or would personally drive MJ there with a car full of teammates so they all could lift his dads spirits, MJ said.

Hixon was there to talk and console MJ. He never left MJ alone, no matter the distance or situation Hixon said.

Jeremiah Hixon touts fellow sophomore receiver Michael Jefferson as Alabama State's best against Tuskegee. A. Stacy Long, Montgomery Advertiser

The team rallied around both King and MJ in different ways, at different times.

Theyve been able as a group to find ways through it, Hill-Eley said. We constantly talk ... and weve been able to repay each out for whats going on and what's happening. Its been a great resource to me, and I know its been a great resource for them. Im 50 and Im trying to understand it, and theyre 19 and 20, so its been a lot of prayers going in and out, but these guys are very strong men, and theyve been able to deal with it.

Through the toughest times, the ASU football team has been there for one another as a team.

Katrice Williams plays around with her son Darius King in front of there home(Photo: Katrice Williams/contributed)

Through the times King would return home and become engrossedin disbelief by his mothers condition, begging for her to get out of bed, Williams said. Through the times shed adhere to his desperate cries, body broken and thinned out by her treatments. He needed to see her strong, Williams said, and he struggled to accept that she was not herself. So, Williams would get up to cook, clean and whatever else it took to prove to him that she wasnt as sick as she was, through the 60 pounds she lost, through her chemo treatments and the up and down nature of her health. Through it all, King thanks guys such as JLan Carson, Christian Clark and Joshua Hill for being there.

Count it all Joy, Part II: ASU LB Darius King helps carry mother's burden, stage 4 cancer

There were other times that Hill-Eley and his staff, present and past, made the clubhouse suites available for Williams during home games, or provided Jefferson Sr. and Williams with a closer parking spot or sent carts to them for transport to and from their cars.

And for that to even occur, Hill-Eley had to make sure he wasnt breaking NCAA rules by accommodating Williams and Jefferson, a tightrope he was willing to walk to give them a little touch of life, he said.

At that point, the human part of you has to kick in, Hill-Eley said. And that gets you past all of these bylaws.

The journey was about selflessness, relatability and empathy.

Alabama State head coach Donald Hill-Eley talks to his team in the first half of an NCAA college football game against Florida State in Tallahassee, Fla., Saturday, Nov. 16, 2019. Florida State won 49-12. (AP Photo/Mark Wallheiser)(Photo: Mark Wallheiser, AP)

MJ and King said they are grateful for all parties involved in this process, and speak for their parents in doing so. Beyond that, they are thankful for a coach like Hill-Eley who took time to make sure they were doing all right amid the many responsibilities of a college head coach.

They called that rare.

On many college teams, head coaches are not that close to players how he is with us, King said. Im just thankful for him.

MJ added: This is one of the best coaches Ive had ... always positive and thats what I need: people with positive energy around me to help me stay up.

These efforts are only a few compared to the many people that were involved in the healing process for MJs, Kings and Hill-Eleys family, and none of the efforts unmentioned went unnoticed.

Today, everyones healing is on the verge of being complete. Jefferson Sr. is expecting his new stem cells to be accepted by his body and is seeing improvement daily, while MJ leads ASU in receiving.

An obstruction in Williams bowel was a cause for concern, and as of last week her oncologist stated that her cancer might be back, but if it is, its too small to show on scans. She will be monitored every three months from now on as a preventative measure. Even so, her son, King, remains in good spirits and says he is humbled and encouraged to live every day like its my last day. Not to be sad or down about it, just keep my head up.

As for Hill-Eley, his father remains in the midst of a battle with throat cancer, and he says its growing, unfortunately, but right after the season he will return home to Virginiato take care of his father. He remains hopeful, however, as the five-year survival rate for his father'scancer is 61%, theASCO says.

Alcorn linebacker Solomon Muhammad (49) snags an interception on a pass intended for ASU wide receiver Tyrek allen (8). (Photo: Kirsten Fiscus/Advertiser)

Alabama State eventually lost that game to Alcorn State at home in early October, but the day wasnt spoiled. Rather, the Hornets counted it all joy, because compared to the trials of life this was just a hiccup and not worthy in the grand scheme, they said.

We needed to see them strong, and they needed to see that we were OK, Hill-Eley said. Just the emotions of seeing them make it another day and to be able to go out and watch their young men play, I know it wasnt the outcome we wanted (againstAlcorn), but the victory was having them in the middle of that field.

Contact Montgomery Advertiser reporter Andre Toranat 334-322-4631or AToran@gannett.com. Follow him on Twitter @AndreToran.

Originally posted here:
Count it all joy, Part III: Coach Hill-Eley has his own cancer struggle - Montgomery Advertiser

To Read More: Count it all joy, Part III: Coach Hill-Eley has his own cancer struggle – Montgomery Advertiser
categoriaBone Marrow Stem Cells commentoComments Off on Count it all joy, Part III: Coach Hill-Eley has his own cancer struggle – Montgomery Advertiser | dataNovember 22nd, 2019
Read All

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Growth, Trends and Demands Research Report and Forecast 2025 – The Denton Chronicle

By daniellenierenberg

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare blood disease of bone marrow stem cells, which are genetically characterized by the somatic mutation in the phosphatidylinositol glycan protein A (PIG-A) gene. PNH generally occurs in the early 30s. Around 10% patients develop PNH symptoms at 21 years of age or earlier. Around 1 to 5 individuals per million people in the U.S. are estimated to suffer from PNH. This is much lower than the incidence rate of bone marrow aplasia. PNH often goes unrecognized; delay in diagnosis may range from one year to more than 10 years.

The global PNH treatment market is anticipated to expand at a rapid pace during the forecast period. It is a niche market, with many pharmaceutical and biotech companies investing in research of bone marrow stem cells. According to current studies, the ideal treatment available is to replace all the hematopoietic stem cells with normal stem cells via stem cells transplantation. However, this treatment is not ideal in some cases as stem cell transplantation requires a stable histocompatible donor.

Complete stem cells transplantation is usually considered in severe cases of PNH, for instance aplastic anemia and transformation to leukemia, as these can be life threatening complications. Factors driving the PNH treatment market include rise in number of blood & bone marrow related disorders, increase in aging population, and technological advancements in stem cells transplantation. However, increase in cost of medical equipment, specifically surgical equipment required for stem cell transformation; lack of reimbursement policies in developing regions; and occurrence of side effects in related current available treatments may hamper the PNH treatment market.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28220

The global PNH treatment market can be segmented based on diagnosis test, type of treatment, drugs, and end-user. In terms of diagnosis test, the market can be divided into complete blood count test (CBC), lactate dehydrogenase test (LDH), bilirubin test, bone marrow examination, urine test for hemosiderin, flow cytometry, and others.

Based on the type of treatment, the PNH treatment market can be segregated into treatment of PNH patients associated with hemolysis, treatment of PNH patients associated with thrombosis, treatment of PNH patients associated with non-hemolytic anemia, allogeneic stem cell transplant (SCT)/bone marrow transplant (BMT), treatment of pregnant PNH patients, treatment of pediatric PNH patients, and others. In terms of drugs, the market can be classified into eculizumab (Soliris), ALXN1210, and others. Based on end-user, the PNH treatment market can be split into hospitals, pharmaceutical & biotech companies, clinics, academic & research institutes, and others.

Geographically, the market for PNH treatment can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). North America dominates the global PNH treatment market due to the rise in the number of blood & bone marrow related diseases, availability of satisfactory reimbursement policies, and increase in awareness about the early diagnosis of the disease in the region.

Ask For A Custom Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=28220

The market in Europe is also expected to expand rapidly, as key players are collaborating with research institutions and labs to develop new innovative products. The PNH treatment market in Asia Pacific is anticipated to expand at a fast pace owing to the unmet needs regarding PNH treatment of the growing population. Additionally, factors such as development of the health care network, rise in disposable income, increase in health care awareness, and availability of reimbursement facilities are boosting the PNH treatment market in Asia Pacific.

Key players operating in the PNH treatment market include Alexion Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., GE Healthcare, and Johnson & Johnson.

Contact Us

Transparency Market ResearchAlbany, NY 12207United StatesTel: +1-518-618-1030Website:www.transparencymarketresearch.comEmail:[emailprotected]Research Blog:https://theglobalhealthnews.com/

Read more:
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Growth, Trends and Demands Research Report and Forecast 2025 - The Denton Chronicle

To Read More: Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Growth, Trends and Demands Research Report and Forecast 2025 – The Denton Chronicle
categoriaBone Marrow Stem Cells commentoComments Off on Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Growth, Trends and Demands Research Report and Forecast 2025 – The Denton Chronicle | dataNovember 22nd, 2019
Read All

Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more – Newswise

By daniellenierenberg

MEDIA CONTACT

Available for logged-in reporters only

For Immediate Release

Newswise SEATTLE Nov. 21, 2019 Fred Hutchinson Cancer Research Centers latest findings on CAR (chimeric antigen receptor) T-cell therapy, gene therapy, precision oncology, immune repair and transplantation will be featured at the 61st American Society of Hematology Annual Meeting and Exposition, which will be held Dec. 710 in Orlando, Florida.

Fred Hutch transplantation physician-scientist Dr. Stephanie Lee will become the new president of ASH at the end of the meeting, T-cell therapy pioneer Dr. Philip Greenberg will give the E. Donnall Thomas Lecture, and Dr. Andrew Cowan will present the latest on a new BCMA, or B-cell maturation antigen, CAR T-cell therapy for multiple myeloma. More details and other meeting highlights can be found below. All presentations will be held in the Orange County Convention Center.

Reporters requesting additional information or interviews, contact Molly McElroy who will be at the conference: mwmcelro@fredhutch.org, 206.941.8146 (cell).

IMMUNOTHERAPY

See preliminary results of a Phase 1 multiple myeloma trial with a CAR T-cell therapy combined with a repurposed Alzheimers drug, discussion of a new CD20 CAR T trial, plus various deep dives on the science of how CD19 CAR T-cell therapy works and how to improve it.

BCMA CAR T-CELL THERAPY / MULTIPLE MYELOMA

Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myelomaFred Hutch scientists are developing a novel immunotherapy approach for multiple myeloma, which involves a CAR T cell that targets BCMA proteins on multiple myeloma cells, plus a drug called a gamma secretase inhibitor, which increases the BCMA target on cancer cells. In an oral presentation, Dr. Andrew Cowan will present promising results from the first cohort of patients on the trial, all of whom responded to the treatment. The researchers published earlier findings of the trial in Blood in September.Abstract No. 204 (oral presentation)Saturday, Dec. 7, 1:15 p.m.Valencia A (W415A), Level 4

Response to BCMA CART cells correlates with pretreatment target density and is improved by small-molecule inhibition of gamma secretase Dr. Damian Green will present findings from multiple myeloma patients that demonstrate a relationship between the number of BCMA targets on multiple myeloma cells and response to a BCMA-directed CAR T-cell therapy. The findings suggest that using a gamma secretase inhibitor to increase the amount of BCMAs on the cell surface could make CAR T work better. Abstract No. 1856 (poster presentation)Saturday, Dec. 7, 5:307:30 p.m.Hall B, Level 2

CD19 CAR T-CELL THERAPIES

With the success of CAR T-cell therapies for some blood cancers, Fred Hutch physician-scientists are taking a closer look to understand how patients respond to the therapy and what could be done to make the treatment work better.

Impact of Lisocabtagene Maraleucel (liso-cel) treatment on health-related quality of life and health utility in patients (pts) with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL): TRANSCEND NHL 001Physician-scientist Dr. David Maloney will present findings from the TRANSCEND trial for CD19 CAR T that show how patients had improved quality-of-life measures (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR Ts and how to deliver them in outpatient settings. He cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutchs clinical-care partner.Abstract No. 66 (poster presentation)Saturday, Dec. 7, 8:45 a.m.W308, Level 3

Factors associated with response, CAR T cell in vivo expansion, and progression-free survival after repeat infusions of CD19 CAR T cellsDoes a second dose of CAR T cells help if the first doesnt lead to a lasting remission? A team of Fred Hutch physician-scientists led by Dr. Cameron Turtleexamined outcomes of 44 patients who received a second cycle of CD19 CAR T-cell immunotherapy for acute lymphoblastic leukemia, chronic lymphocytic leukemia or non-Hodgkin lymphoma. The type of chemotherapy given before the first infusion of CAR T cells and a higher dose of CAR T cells for the second infusion were associated with better outcomes.Abstract No. 201 (oral presentation)Saturday, Dec. 7, 12:30 p.m.Valencia A (W415A), Level 4

Severe cytokine release syndrome is associated with impaired hematopoietic recovery after CD19-targeted CART-cell therapyDr. Krishna Juluri, a hematology-oncology fellow at Fred Hutch, will discuss how blood cells recover following CAR T treatment. The researchers found patients who experienced more severe cytokine release syndrome had slower recovery of blood counts. Since CRS can be treated, the Fred Hutch team concludes preventing it might improve blood-cell recovery.Abstract No. 3229 (poster presentation)Sunday, Dec. 8, 68 p.m.Hall B, Level 2

Combination of NKTR-255, a polymer-conjugated human IL-15, with CD19 CAR T-cell immunotherapy in a preclinical lymphoma modelDr. Cassie Chou will present preclinical studies that show how a novel IL-15 receptor agonist activates the interleukin 15 immune system pathway to enhance growth and anti-tumor efficacy of human CD19 CAR T cells in immunodeficient mice bearing human lymphoma. Future clinical trials will explore whether the compound can improve responses to CAR T-cell therapy. Chou is a research fellow and clinician who works in the lab ofDr. Cameron Turtle. Abstract No. 2866 (poster presentation)Sunday, Dec. 8, 68 p.m.Hall B, Level 2

Relapsed or refractory CLL after CD19-specific CART therapy: Treatment patterns and clinical outcomesTreating high-risk chronic lymphocytic leukemia remains challenging with a 65% relapse rate following CAR T-cell therapy. Looking at outcomes of patients with progressive disease after CAR-T, Dr. Mazyar Shadman reports that CAR T-cell therapy did not work as well for patients who had already been treated with more than one other therapy for CLL. This study defines a benchmark for future trials that target relapsed CLL after CAR-T, and it also argues for referring patients to CAR T before they have exhausted other therapeutic options.Abstract No. 4294 (poster presentation)Monday, Dec. 9, 68 p.m.Hall B, Level 2

CD20 CAR T-CELL THERAPY

CD20 targeted chimeric antigen receptor T cells for treatment of high-risk B-cell non-Hodgkin lymphomasMost CAR T-cell therapies for blood cancers target a cancer-specific protein marker called CD19. But more targets are needed. Another CAR T-cell therapy that targets the CD20 protein on cancer cells is being developed by Fred Hutch scientists. Dr. Mazyar Shadman will give an overview of the trial, which is recruiting patients at the Hutchs clinical-care partner, Seattle Cancer Care Alliance. Results of the trial are not ready and will not be reported at ASH.Abstract No. 3235 (poster presentation)Sunday, Dec. 8, 68 p.m.Hall B, Level 2

_____________________________________________________________________________________________________________________

TRANSPLANTATION

Extending the benefit of transplantation to more patientsSirolimus combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As graft-vs-host disease (GVHD) prophylaxis after nonmyeloablative (NMA) hematopoietic cell transplantation (HCT) using HLA Class I or Class II antigen mismatched donors: Results from a Phase II multicenter trialStem cell transplants can save lives, but their success depends on the availability of compatible donors. Unfortunately, depending upon ethnicity, fully HLA-matched donors cannot be found for 25-84% of patients. Dr. Brenda Sandmaier is presenting results from a Phase 2 trial that shows how a triple-drug combination improves outcomes for patients treated with mismatched donors. Abstract No. 369 (oral presentation)Sunday, Dec. 8, 8 a.m.W230, Level 2

Cord blood transplantationTransplantation of blood stem cells from umbilical cord blood can treat blood disorders in patients who have been unable to find a suitable match among other donor sources. This is particularly true for patients of mixed ethnicities. Dr. Filippo Milano, associate director of Fred Hutchs Cord Blood Program, is involved in the following presentations.

_______________________________________________________________________________________________________________________

GENE THERAPY

Scientists in the lab of Dr. Hans-Peter Kiem, director of Fred Hutchs Stem Cell and Gene Therapy Program, are pioneering a variety of gene therapy approaches for HIV/AIDS, sickle cell anemia, blood cancers and other diseases. Below are their presentation abstracts.

Fully closed, large-scale, and clinical grade cell sorting of hematopoietic stem cell (HSC)-enriched CD90+ cells for transplantation and gene therapyDr. Stefan Radtke, a Fred Hutch staff scientist, will show for the first time in human blood samples how to isolate a rare stem cell subset that Fred Hutch researchers identified as capable of repopulating the entire blood and immune system. He used commercially available cell-sorting equipment to isolate the cells, an approach that has the potential to make gene therapy more efficient and affordable.Abstract No. 3246 (poster presentation)Sunday, Dec. 8, 68 p.m.Hall B, Level 2

CRISPR/Cas9-mediated protection of normal hematopoiesis combined with the CD33/CD3 bispecific T-cell engager (BiTE) antibody AMG330 for improved AML therapyCD33, a protein marker of cancerous cells in acute myeloid leukemia, is also found on healthy blood stem cells, which makes targeting CD33 toxic, as it kills both healthy cells and cancerous ones. Dr. Olivier Humbert, a staff scientist, used CRISPR to remove the CD33 target from healthy cells. Then, in a mouse model of acute myeloid leukemia, he found that T cells effectively use the CD33 bispecific T-cell engager (BiTE) antibody to attack cancer while sparing CRISPR-edited healthy cells.Abstract No. 4427 (poster presentation)Monday, Dec. 9, 68 p.m.Hall B, Level 2 _______________________________________________________________________________________________________________________

PRECISION MEDICINE / PEDIATRIC AML

Researchers from the lab of Dr. Soheil Meshinchi, a pediatric oncologist and acute myeloid leukemia specialist, will present oral presentations that map genetic mutations to patient outcomes. He says the ongoing genomic profiling work can help guide targeted treatments for patients with AML, the deadliest leukemia among children and young adults.

_______________________________________________________________________________________________________________________

ASH NOTABLES

ASH E. Donnall Thomas Lecture and PrizeThe long road to develop adoptive therapy for T cells that can effectively target acute myeloid leukemia and other malignanciesAt the annual E. Donnall Thomas Lecture, Dr. Philip Greenberg, head of the Program in Immunology at Fred Hutch, will talk about how T cells have been engineered to target acute myeloid leukemia and our latest understanding of why cell therapies like CAR T-cell therapy work for some patients and not others, but can potentially be engineered to overcome these obstacles. ASHs E. Donnall Thomas Lecture and Prize recognizes pioneering research achievements in hematology that have changed the field and is named for the Hutchs Dr. E. Donnall Thomas, who received a Nobel Prize for his pioneering efforts in bone marrow transplantation. Thomas was also a colleague and mentor to Greenberg. Learn more about the lecture in an ASH news release.Monday, Dec. 9, 910 a.m.Hall D, Level 2

Incoming ASH President Dr. Stephanie LeeASH will recognize Dr. Stephanie Lee, a hematologist and transplant physician-scientist at Fred Hutch, as its new president at the societys business meeting. Lee cares for stem cell transplant patients at the Hutchs clinical-care partner, Seattle Cancer Care Alliance, and at UW Medicine. Her research aims to improve the lives of transplant recipients. Lee directs the Hutchs Long-Term Follow-Up Research Program, which tracks the outcomes of more than 5,000 transplant survivors.Tuesday, Dec. 10, 11:1511:30 a.mHall D, Level 2

________________________________________________________________________________________________________________________

ON THE HORIZON / OTHER ABSTRACTS

Other notable experts and newsy topics at ASH:

Chronic myeloid leukemia: Meeting global need with better molecular testingDr. Jerald Radich is a medical oncologist who specializes in chronic myeloid leukemia, a relatively rare, slow-growing cancer that is fatal if left untreated. His Fred Hutch research lab examines the molecular genetics of leukemias in an effort to develop methods to improve the detection and treatment of the disease. At an ASH education session, Radich will talk about his award-winning collaboration with The Max Foundation, a Seattle-area nonprofit, which has led to more people in under-resourced areas being tested for CML. He will also give an oral presentation about a molecular test he developed that can predict which CML patients will have a sustained, deep molecular response to treatment.

Repairing immune function

Underappreciated by most, the thymus is a gland in the chest that acts like a boot camp for T cells, training them to identify and kill foreign invaders. The gland wears out with stress, infection and age, and finding ways to boost its productivity could help sustain human health. Researchers in the lab of Dr. Jarrod Dudakov, a Fred Hutch immunologist, will present the latest in understanding the signaling pathways of the thymus. Discovering master regulators could be targets for helping the thymus to repair itself. Below are their presentation abstracts.

_________________________________________________________________________________________________________________________

Note: Fred Hutch and its scientists who contributed to these discoveries may stand to benefit from their commercialization. See links above to ASH abstracts for more details on individual researchers disclosures.

The clinical trials referenced above involve investigational products and/or therapies that have not been approved for commercial marketing by the U.S. Food and Drug Administration or any other regulatory authority. Results may vary, and encouraging results from early-stage clinical trials may not be supported in later-stage clinical trials. No conclusions should be drawn from the information in this report about the safety, efficacy or likelihood of regulatory approval of these investigational products and/or therapies.

# # #

Media Contact:Molly McElroyO: 206.667.2210M: 206.941.8146mwmcelro@fredhutch.org

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of the HIV Vaccine Trials Network.

Read the rest here:
Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more - Newswise

To Read More: Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more – Newswise
categoriaBone Marrow Stem Cells commentoComments Off on Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more – Newswise | dataNovember 22nd, 2019
Read All

Brainstorm Cell Therapeutics (BCLI) Gets a Buy Rating from Maxim Group – Smarter Analyst

By daniellenierenberg

Maxim Group analyst Jason McCarthy maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI) yesterday and set a price target of $9.00. The companys shares closed last Monday at $3.92.

According to TipRanks.com, McCarthy s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -22.1% and a 25.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Lineage Cell Therapeutics.

Brainstorm Cell Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.

See todays analyst top recommended stocks >>

Based on Brainstorm Cell Therapeutics latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.63 million. In comparison, last year the company had a GAAP net loss of $3.18 million.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCLI in relation to earlier this year. Most recently, in August 2019, Irit Arbel, a Director at BCLI sold 13,332 shares for a total of $48,795.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinsons disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Go here to read the rest:
Brainstorm Cell Therapeutics (BCLI) Gets a Buy Rating from Maxim Group - Smarter Analyst

To Read More: Brainstorm Cell Therapeutics (BCLI) Gets a Buy Rating from Maxim Group – Smarter Analyst
categoriaBone Marrow Stem Cells commentoComments Off on Brainstorm Cell Therapeutics (BCLI) Gets a Buy Rating from Maxim Group – Smarter Analyst | dataNovember 22nd, 2019
Read All

AI helps cells pull themselves together – Cosmos

By daniellenierenberg

By Paul Biegler

US scientists have overcome a major stumbling block in the creation of mini-organs, programming cells to take on the desired shape rather than relying on 3D printing or external scaffolds.

This inside out approach, described in a paper in the journal Cell Systems, could signal a paradigm shift in how mini-hearts, kidneys and brains are grown on the lab bench a technique used to study disease that may one day lead to personalised organ transplants.

The team, led by bioengineer Todd McDevitt at Gladstone Institutes in the US, was driven by an enduring issue with state-of-the-art ways of producing mini-organs such as 3D printing. The cells just wont stay put.

Making a mini-organ or organoid starts when scientists take a persons skin cell and, using the right mix of agents, turn it into an induced pluripotent stem cell. This IPS cell is the blank cheque of biology, capable of becoming almost any cell type.

Grow it into a mini-kidney, say, and you can reproduce kidney diseases and test treatments in a dish sitting on your lab bench. But how faithful that model is depends on the physical organisation of the cells; to mimic a real deal kidney, 3D printing is often used.

But cells, much like unruly teenagers, have a mind of their own and will often wander away from their printed position.

McDevitts team wanted to own those cellular minds and so took control of two genes that together make up something of a joystick that directs how the cells organise.

CDH1 and ROCK1 figure heavily in the complex moves that lead to the final configuration of a group of cells. The pair influences stickiness and repulsion between cells, the surface tension that makes them spherical and their overall speed of migration.

The researchers used the editing tool CRISPR to knock out the two genes at various stages in the evolution of a clump of cells. Their aim was to make a bulls eye pattern, a shape thats common in human development, including in early embryo formation.

To detect that aspirational pattern, they engineered another tweak making the cells fluoresce when CDH1 and ROCK1 were neutralised.

But there was a problem.

Factor in all the potential time points where the genes could be knocked out, the proportion of cells to be targeted, and a host of other variables, and the researchers calculated theyd need to do nearly 9000 trial-and-error experiments.

So they called on AI. They trained a machine learning model to compute the precise pattern of gene knockouts needed to realise their dream shape.

Machine learning can predict what movie you might like based on your viewing history, but it can also generate new insights into biological systems by mimicking them, says co-author Demarcus Briers, from the Boston University Bioinformatics Program.

Our machine-learning model allows us to predict new ways that stem cells can organise themselves, and produces instructions for how to recreate these predictions in the lab.

That model hit a bulls eye, quite literally, allowing the team to produce the concentric pattern of cells they were aiming at.

"We've shown how we can leverage the intrinsic ability of stem cells to organise," says McDevitt. "This gives us a new way of engineering tissues, rather than a printing approach where you try to physically force cells into a specific configuration."

Ultimately, that concrete target shape will give way to a target in the abstract, one with potential to shift the life course.

"We're now on the path to truly engineering multicellular organization, which is the precursor to engineering organs," McDevitt says. "When we can create human organs in the lab, we can use them to study aspects of biology and disease that we wouldn't otherwise be able to."

Link:
AI helps cells pull themselves together - Cosmos

To Read More: AI helps cells pull themselves together – Cosmos
categoriaSkin Stem Cells commentoComments Off on AI helps cells pull themselves together – Cosmos | dataNovember 20th, 2019
Read All

Page 10«..9101112..2030..»